快速开发针对新发病原体的疫苗:复制缺陷型猿腺病毒平台技术
本文综述了复制缺陷型猿腺病毒作为疫苗平台在快速应对新发病原体方面的应用,描述了针对埃博拉病毒、裂谷热病毒和中东呼吸综合征冠状病毒的人用和兽用疫苗开发进展。2014年埃博拉大暴发时无可用疫苗或药物,多种候选疫苗并行临床开发,但仅一种进入III期试验。平台技术可加速疫苗开发并促进快速进入临床试验及疫苗储备。
要点
- 2014年埃博拉大暴发时无可用疫苗或药物,多种候选疫苗并行开发,仅一种进入III期试验。
- 复制缺陷型猿腺病毒平台可用于快速开发针对新发病原体的疫苗。
- 该平台已用于埃博拉病毒、裂谷热病毒和中东呼吸综合征冠状病毒的人用和兽用疫苗开发。
核心结论
- 为更好地应对已知人类病原体的未来暴发,应采用平台技术加速疫苗开发,使开发者能利用对疫苗平台的详尽知识,促进快速进入临床试验并最终形成疫苗储备。
研究设计与样本
- 本文为综述,以复制缺陷型猿腺病毒为疫苗平台示例,描述针对埃博拉病毒、裂谷热病毒和中东呼吸综合征冠状病毒的人用和兽用疫苗开发进展。
主要发现
- 2014年埃博拉大暴发时无可用疫苗或药物,多种候选疫苗的临床开发与控制暴发的努力并行启动,但最终仅一种疫苗在III期试验中 tested。
- 综述描述了复制缺陷型猿腺病毒平台在埃博拉病毒、裂谷热病毒和中东呼吸综合征冠状病毒的人用和兽用疫苗开发中的进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the fact that there had been multiple small outbreaks of Ebola Virus Disease, when a large outbreak occurred in 2014 there were no vaccines or drugs available for use. Clinical development of multiple candidate vaccines was then initiated in parallel with attempts to contain the outbreak but only one vaccine was eventually tested in a phase III trial. In order to be better prepared for future outbreaks of known human pathogens, platform technologies to accelerate vaccine development should be employed, allowing vaccine developers to take advantage of detailed knowledge of the vaccine platform and facilitating rapid progress to clinical trials and eventually to vaccine stockpiles. This review gives an example of one such vaccine platform, replication-deficient simian adenoviruses, and describes progress in human and livestock vaccine development for three outbreak pathogens, Ebola virus, Rift Valley Fever Virus and Middle East Respiratory Syndrome Coronavirus.
引用
- Gilbert SC, Warimwe GM. Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. Vaccine. 2017. PMID: 28576573. doi:10.1016/j.vaccine.2017.04.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。